版本:
中国

BRIEF-Argos therapeutics provides update on ADAPT trial following meeting with FDA

May 10 Argos Therapeutics Inc

* Argos provides update on its ADAPT trial following meeting with FDA

* Argos Therapeutics Inc- FDA agreed with company's plan to continue trial in accordance with current protocol to 290 events

* Argos Therapeutics - FDA agreed to review, protocol amendment to increase pre-specified number of events for primary analysis of OS beyond 290 events

* Argos - submitted information on analysis of interim data to fda, met to discuss future direction of ADAPT trial, rocapuldencel-t development program Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐